Revium Rx (RVRC) Gains from Investment Securities (2024 - 2025)

Revium Rx's (RVRC) quarterly Gains from Investment Securities came in at $690000.0 in Q4 2025, down 6.76% year-on-year from $740000.0 in Q4 2024, and down 6.76% quarter-over-quarter from $740000.0 in Q4 2024.

Revium Rx (RVRC) Gains from Investment Securities (2024 - 2025) Analysis & Trends

Revium Rx has disclosed Gains from Investment Securities across 2 years of filings, most recently posting $690000.0 for Q4 2025.

  • Gains from Investment Securities for Q4 2025 came in at $690000.0, down 6.76% year-over-year; the trailing twelve-month figure through Dec 2025 was $690000.0 (down 6.76% YoY), and the FY2025 annual result was $690000.0, down 6.76% from the prior year.
  • Gains from Investment Securities came in at $690000.0 for Q4 2025 at Revium Rx, down from $740000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $740000.0 in Q4 2024 to a low of $690000.0 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Veeva Systems 24.83 Bn 17.52 Bn 662.02 Mn
2 BrightSpring Health Services 13.57 Bn 12.69 Bn 482.22 Mn
3 Healthequity 7.20 Bn 6.93 Bn 256.31 Mn
4 Hinge Health 5.42 Bn 5.11 Bn 154.23 Mn
5 10x Genomics 4.46 Bn 3.92 Bn 106.18 Mn
6 Doximity 3.81 Bn 3.06 Bn 125.97 Mn
7 Waystar Holding 3.52 Bn 3.36 Bn 268.04 Mn
8 Privia Health 2.94 Bn 2.57 Bn 595.71 Mn
9 Omnicell 1.76 Bn 1.59 Bn 140.36 Mn
10 Revium Rx - - -

Historic Data

Download Data
DateValue
Dec 31, 2025 690,000.00
Dec 31, 2025 690,000.00
Dec 31, 2024 740,000.00
Dec 31, 2024 740,000.00